FDA peptide panel stacked with RFK Jr allies, what this means for access
Posted by amber464 in Research & News - 1 points, 4 comments.
https://apnews.com/article/peptides-fda-rfk-jr-drugs-wellness-dc3eeb67358373d580529c50784af109
AP is reporting the FDA peptide advisory committee will include several voices who have publicly pushed unproven peptide protocols the kind RFK Jr has promoted. This is not a drill the regulatory framework for compounded peptides is being rewritten in real time and the panel composition signals which way the wind is blowing. I have been tracking the FDA docket for months and the timing aligns with the 503A/503B guidance revisions.
What concerns me is the lack of clinical pharmacologists or toxicologists on the roster. We are talking about compounds with zero Phase 3 data being evaluated by people who have financial ties to peptide clinics. That is not safety oversight that is regulatory capture.
My lab has seen a spike in "research only" peptides showing up with questionable purity certificates since the compounding crackdown started. If this panel rubber stamps expanded access without mandatory third party testing we are going to see more contaminated batches and more adverse events that get blamed on the molecules instead of the supply chain. Question for the group how many of you have actually pulled a COA from your source in the last six months and what did it show?
Comments
- aspiring_trailrun: The FDA panel makeup is worrying even from over here. What happens stateside tends to ripple into UK supply chains within months. I started requesting COAs on every vial last year after a batch of BPC-157 came back with only a generic HPLC trace, no mass spec, no endotoxin panel. The supplier ghosted me when I asked for the raw data. Since switching to a source that posts full third party reports publicly my own results have been far more consistent. Could be placebo but the peace of mind is re
- amber464: that tracks with what we are seeing stateside. the COA situation got weird fast after the compounding crackdown. my lab pulled a batch of research peptides last month that had a clean HPLC but zero mass spec data and the endotoxin field was just blank. supplier said it was a formatting error but we flagged it anyway. imo the ghosting when you ask for raw data is the biggest red flag. we started requiring the full PDF packet before we even log a vial. what third party lab does your current sourc
- aspiring_codes: Yeah, that blank endotoxin field would make me side eye it too. Clean HPLC alone doesnt buy much reassurance if the rest of the packet is mush. Ive seen the same thing, the second you ask for raw data or method details, some suppliers get real quiet. That alone is enough for me to pass. The source matters less than whether they can show the full paperwork without dancing around it.
- amber464: Yep, exactly. That blank endotoxin field was the part that made me stop and stare, not the HPLC pretty picture. In my lab, if the method section is vague or they wonât show raw data, I treat it like a red flag and move on. And yeah, that âget real quietâ thing is the whole game. Same here, once you ask for lot-specific details or how they measured anything, the story usually falls apart. Iâm watching whether this panel changes the paperwork standards at all, because right now the noise is loud
Community discussion - research and educational context only. Not medical advice.